The genetic landscape of Parkinson's disease
The DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
Abstract
The cause of Parkinson's disease (PD) remains unknown in most patients. Since 1997, with the first genetic mutation known to cause PD described in SNCA gene, many other genes with Mendelian inheritance have been identified. We summarize genetic, clinical and neuropathological findings related to the 27 genes reported in the literature since 1997, associated either with autosomal dominant (AD): LRRK2, SNCA, VPS35, GCH1, ATXN2, DNAJC13, TMEM230, GIGYF2, HTRA2, RIC3, EIF4G1, UCHL1, CHCHD2, and GBA; or autosomal recessive (AR) inheritance: PRKN, PINK1, DJ1, ATP13A2, PLA2G6, FBXO7, DNAJC6, SYNJ1, SPG11, VPS13C, PODXL, and PTRHD1; or an X-linked transmission: RAB39B. Clinical and neuropathological variability among genes is great. LRRK2 mutation carriers present a phenotype similar to those with idiopathic PD whereas, depending on the SNCA mutations, the phenotype ranges from early onset typical PD to dementia with Lewy bodies, including many other atypical forms. DNAJC6 nonsense mutations lead to a very severe phenotype whereas DNAJC6 missense mutations cause a more typical form. PRKN, PINK1 and DJ1 cases present with typical early onset PD with slow progression, whereas other AR genes present severe atypical Parkinsonism. RAB39B is responsible for a typical phenotype in women and a variable phenotype in men. GBA is a major PD risk factor often associated with dementia. A growing number of reported genes described as causal genes (DNAJC13, TMEM230, GIGYF2, HTRA2, RIC3, EIF4G1, UCHL1, and CHCHD2) are still awaiting replication or indeed have not been replicated, thus raising questions as to their pathogenicity. Phenotypic data collection and next generation sequencing of large numbers of cases and controls are needed to differentiate pathogenic dominant mutations with incomplete penetrance from rare, non-pathogenic variants. Although known genes cause a minority of PD cases, their identification will lead to a better understanding their pathological mechanisms, and may contribute to patient care, genetic counselling, prognosis determination and finding new therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529 · cited 1×
“The disease manifests when approximately 70% of neurons in the substantia nigra have degenerated [3] and includes”
BackgroundHereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481 · cited 1×
“the second most frequent gene involved in autosomal recessive PD with typical phenotype and early onset [122].”
BackgroundMutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778 · cited 7×
“DJ1 [124], few patients with DJ1 mutations have been reported but it still remains the third most frequent autosomal recessive early onset PD gene after PRKN and PINK1.”
BackgroundInfluentialSelf-citationThe new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405 · cited 1×
“[9] Paisán-Ruiz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M, et al.”
BackgroundMulticenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Self-citationFamilial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024 · cited 3×
“[107] Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, et al.”
BackgroundInternational Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895
Self-citationα-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro
Burré, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M. R., & Südhof, T. C. (2010) · Science · doi:10.1126/science.1195227 · Cited by 1,812
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570 · cited 1×
“[5] Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, et al.”
BackgroundAssociation between Early-Onset Parkinson's Disease and Mutations in the Parkin Gene
Lücking, C. B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B. S., Meco, G., Denèfle, P., Wood, N. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005253422103 · Cited by 1,433 · cited 2×
“[114] Lücking CB, Dürr A, Bonifati V, Vaughan J, De Michele G, Gasser T, et al.”
BackgroundSelf-citationHealy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425 · cited 2×
“The response to levodopa therapy was similar within these two groups: 88% of LRRK2 mutated patients showed a positive response, compared with 83% of IPD patients [16].”
BackgroundResultSelf-citationAlzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A.-L., Roeper, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1884 · Cited by 1,208 · cited 2×
“Different types of mutations were initially described in Kufor-Rakeb syndrome, namely missense, nonsense or frameshift mutations [128].”
BackgroundParkinson's disease: from monogenic forms to genetic susceptibility factors
Lesage, S., & Brice, A. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp012 · Cited by 945
Self-citationInsulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
A Mutation in VPS35, Encoding a Subunit of the Retromer Complex, Causes Late-Onset Parkinson Disease
Zimprich, A., Benet-Pagès, A., Struhal, W., Graf, E., Eck, S. H., Offman, M. N., Haubenberger, D., Spielberger, S., Schulte, E. C., Lichtner, P., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.06.008 · Cited by 816 · cited 1×
“[49] Zimprich A, Benet-Pagès A, Struhal W, Graf E, Eck SH, Offman MN, et al.”
BackgroundVPS35 mutations in Parkinson disease
Vilariño-Güell, C., Wider, C., Ross, O. A., Dachsel, J. C., Kachergus, J. M., Lincoln, S. J., Soto-Ortolaza, A. I., Cobb, S. A., Wilhoite, G. J., Bacon, J. A., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.06.001 · Cited by 800 · cited 1×
“[48] Vilariño-Güell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, et al.”
BackgroundG51D α‐synuclein mutation causes a novel Parkinsonian–pyramidal syndrome
Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honoré, A., Rozas, N., Pieri, L., Madiona, K., Dürr, A., Melki, R., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23894 · Cited by 711
Self-citationGlucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696 · cited 24×
“The p.Ala53Thr mutation, which is the most frequent SNCA mutation, causes early onset PD (before age 50 years), sometimes resembling IPD but often associated with dementia [34–36].”
BackgroundInfluentialAlpha‐synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease
Appel‐Cresswell, S., Vilarino‐Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah, B., Weir, D., Thompson, C., Szu‐Tu, C., Trinh, J., et al. (2013) · Movement Disorders · doi:10.1002/mds.25421 · Cited by 667
The link between the GBA gene and parkinsonism
Sidransky, E., & Lopez, G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70190-4 · Cited by 583 · cited 1×
“the major predictor of cognitive decline in PD [177].”
BackgroundLoss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease
Strauss, K. M., Martins, L. M., Plun-Favreau, H., Marx, F. P., Kautzmann, S., Berg, D., Gasser, T., Wszolek, Z., Müller, T., Bornemann, A., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi215 · Cited by 568 · cited 2×
“Gly399Ser variant without confirmation in large-scale studies [81,82].”
BackgroundPasanen, P., Myllykangas, L., Siitonen, M., Raunio, A., Kaakkola, S., Lyytinen, J., Tienari, P. J., Pöyhönen, M., & Paetau, A. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.024 · Cited by 536
PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron
Morgan, N. V., Westaway, S. K., Morton, J. E. V., Gregory, A., Gissen, P., Sonek, S., Cangul, H., Coryell, J., Canham, N., Nardocci, N., et al. (2006) · Nature Genetics · doi:10.1038/ng1826 · Cited by 533 · cited 2×
“accumulation (NBIA2) and Karak syndrome [138,139].”
BackgroundA frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease
Di Fonzo, A., Rohé, C. F., Ferreira, J., Chien, H. F., Vacca, L., Stocchi, F., Guedes, L., Fabrizio, E., Manfredi, M., Vanacore, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17829-5 · Cited by 531 · cited 1×
“[20] Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, Stocchi F, et al.”
BackgroundMitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease
Ryan, B. J., Hoek, S., Fon, E. A., & Wade-Martins, R. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.02.003 · Cited by 524 · cited 3×
“[106] Ryan BJ, Hoek S, Fon EA, Wade-Martins R.”
BackgroundCollaborative Analysis of α-Synuclein Gene Promoter Variability and Parkinson Disease
Maraganore, D. M. (2006) · JAMA · doi:10.1001/jama.296.6.661 · Cited by 508
LRRK2 G2019S as a Cause of Parkinson's Disease in North African Arabs
Lesage, S., Dürr, A., Tazir, M., Lohmann, E., Leutenegger, A.-L., Janin, S., Pollak, P., & Brice, A. (2006) · New England Journal of Medicine · doi:10.1056/nejmc055540 · Cited by 494 · cited 2×
“more than one-third of North African cases [11,12].”
BackgroundSelf-citationLewy bodies and parkinsonism in families with parkin mutations
Farrer, M., Chan, P., Chen, R., Tan, L., Lincoln, S., Hernandez, D., Forno, L., Gwinn‐Hardy, K., Petrucelli, L., Hussey, J., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1132 · Cited by 485 · cited 2×
“The major difference with IPD is neuropathological: cases with PARK2 present neuronal loss predominantly in the ventral substantia nigra and very few of them have Lewy bodies [119,120].”
BackgroundCharacterization of PLA2G6 as a locus for dystonia‐parkinsonism
Paisan‐Ruiz, C., Bhatia, K. P., Li, A., Hernandez, D., Davis, M., Wood, N. W., Hardy, J., Houlden, H., Singleton, A., & Schneider, S. A. (2009) · Annals of Neurology · doi:10.1002/ana.21415 · Cited by 480 · cited 1×
“[144] Paisan-Ruiz C, Bhatia KP, Li A, Hernandez D, Davis M, Wood NW, et al.”
BackgroundA novel α-synuclein missense mutation in Parkinson disease
Proukakis, C., Dudzik, C. G., Brier, T., MacKay, D. S., Cooper, J. M., Millhauser, G. L., Houlden, H., & Schapira, A. H. (2013) · Neurology · doi:10.1212/wnl.0b013e31828727ba · Cited by 449
Lesage, S., Drouet, V., Majounie, E., Deramecourt, V., Jacoupy, M., Nicolas, A., Cormier-Dequaire, F., Hassoun, S. M., Pujol, C., Ciura, S., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.01.014 · Cited by 434 · cited 1×
“[165] Lesage S, Drouet V, Majounie E, Deramecourt V, Jacoupy M, Nicolas A, et al.”
BackgroundSelf-citationRobust Pacemaking in Substantia Nigra Dopaminergic Neurons
Guzman, J. N., Sánchez-Padilla, J., Chan, C. S., & Surmeier, D. J. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2519-09.2009 · Cited by 411 · cited 1×
“[6] Guzman JN, Sanchez-Padilla J, Chan CS, Surmeier DJ.”
Gaucher disease: complexity in a “simple” disorder
Sidransky, E. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.08.015 · Cited by 399 · cited 1×
“A neuropathological study of Gaucher’s disease cases showed the presence of Lewy bodies [172].”
BackgroundMartins, L. M., Morrison, A., Klupsch, K., Fedele, V., Moisoi, N., Teismann, P., Abuin, A., Grau, E., Geppert, M., Livi, G. P., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.22.9848-9862.2004 · Cited by 394 · cited 2×
“[80] Martins LM, Morrison A, Klupsch K, Fedele V, Moisoi N, Teismann P, et al.”
BackgroundThe role of pathogenic DJ‐1 mutations in Parkinson's disease
Abou‐Sleiman, P. M., Healy, D. G., Quinn, N., Lees, A. J., & Wood, N. W. (2003) · Annals of Neurology · doi:10.1002/ana.10675 · Cited by 383
Clinical and genetic delineation of neurodegeneration with brain iron accumulation
Gregory, A., Polster, B. J., & Hayflick, S. J. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061929 · Cited by 364 · cited 2×
“[139] Gregory A, Polster BJ, Hayflick SJ.”
FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome
Fonzo, A. D., Dekker, M. C. J., Montagna, P., Baruzzi, A., Yonova, E. H., Guedes, L. C., Szczerbinska, A., Zhao, T., Dubbel-Hulsman, L. O. M., Wouters, C. H., et al. (2009) · Neurology · doi:10.1212/01.wnl.0000338144.10967.2b · Cited by 364 · cited 3×
“FBXO7 patients present juvenile parkinsonism associated with pyramidal signs (PARK15) [161].”
BackgroundParkin disease: a phenotypic study of a large case series
Khan, N. L., Graham, E., Critchley, P., Schrag, A. E., Wood, N. W., Lees, A. J., Bhatia, K. P., & Quinn, N. (2003) · Brain · doi:10.1093/brain/awg142 · Cited by 352 · cited 3×
“[116] Khan NL, Graham E, Critchley P, Schrag AE, Wood NW, Lees AJ, et al.”
BackgroundFunayama, M., Ohe, K., Amo, T., Furuya, N., Yamaguchi, J., Saiki, S., Li, Y., Ogaki, K., Ando, M., Yoshino, H., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70266-2 · Cited by 351 · cited 2×
“CHCHD2 mutation carriers presented with typical PD with a variable age at onset (range: 39 to 52 years) [96].”
BackgroundLRRK2 kinase in Parkinson's disease
Alessi, D. R., & Sammler, E. (2018) · Science · doi:10.1126/science.aar5683 · Cited by 345 · cited 2×
“LRRK2/dardarin is involved in many processes, such as the lysosomal pathway and autophagy regulation [10].”
BackgroundNeuropathology of genetic synucleinopathies with parkinsonism: Review of the literature
Schneider, S. A., & Alcalay, R. N. (2017) · Movement Disorders · doi:10.1002/mds.27193 · Cited by 342 · cited 1×
“The phenotype of SNCA patients varies greatly according to the mutations, ranging from typical PD to early onset dementia with Lewy bodies, but all cases with SNCA mutations bear the same neuropathological hallmarks: Lewy bodies, Lewy neurites and neuronal loss in the substantia nigra pars compacta, which may vary in…”
BackgroundThe Parkinson's disease–linked proteins Fbxo7 and Parkin interact to mediate mitophagy
Burchell, V. S., Nelson, D. E., Sanchez-Martinez, A., Delgado-Camprubi, M., Ivatt, R. M., Pogson, J. H., Randle, S. J., Wray, S., Lewis, P. A., Houlden, H., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3489 · Cited by 341 · cited 3×
“FBXO7 encodes F-box protein 7, which is involved in mitochondrial maintenance in interaction with PINK1 and Parkin [159].”
BackgroundInfluentialLysosomal impairment in Parkinson's disease
Dehay, B., Martinez‐Vicente, M., Caldwell, G. A., Caldwell, K. A., Yue, Z., Cookson, M. R., Klein, C., Vila, M., & Bezard, E. (2013) · Movement Disorders · doi:10.1002/mds.25462 · Cited by 340
ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease
Di Fonzo, A., Chien, H. F., Socal, M., Giraudo, S., Tassorelli, C., Iliceto, G., Fabbrini, G., Marconi, R., Fincati, E., Abbruzzese, G., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000260963.08711.08 · Cited by 339 · cited 5×
“The symptoms at onset were highly variable, encompassing akineto-rigid syndrome [129,130], learning disability [131], motor fine task impairment [132,133] or behavioural disturbances [134].”
BackgroundInfluentialKrebs, C. E., Karkheiran, S., Powell, J. C., Cao, M., Makarov, V., Darvish, H., Di Paolo, G., Walker, R. H., Shahidi, G. A., Buxbaum, J. D., et al. (2013) · Human Mutation · doi:10.1002/humu.22372 · Cited by 336 · cited 3×
“The phenotype includes parkinsonism with poor response to levodopa or early onset of treated-induced dyskinesias [113,154,155].”
BackgroundMutation in the SYNJ1 Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism
Quadri, M., Fang, M., Picillo, M., Olgiati, S., Breedveld, G. J., Graafland, J., Wu, B., Xu, F., Erro, R., Amboni, M., et al. (2013) · Human Mutation · doi:10.1002/humu.22373 · Cited by 320 · cited 2×
“[156] Quadri M, Fang M, Picillo M, Olgiati S, Breedveld GJ, Graafland J, et al.”
BackgroundEdvardson, S., Cinnamon, Y., Ta-Shma, A., Shaag, A., Yim, Y.-I., Zenvirt, S., Jalas, C., Lesage, S., Brice, A., Taraboulos, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036458 · Cited by 318 · cited 4×
“[148] Edvardson S, Cinnamon Y, Ta-Shma A, Shaag A, Yim Y-I, Zenvirt S, et al.”
BackgroundInfluentialSelf-citationKasten, M., Hartmann, C., Hampf, J., Schaake, S., Westenberger, A., Vollstedt, E., Balck, A., Domingo, A., Vulinovic, F., Dulovic, M., et al. (2018) · Movement Disorders · doi:10.1002/mds.27352 · Cited by 316
DNAJC13 mutations in Parkinson disease
Vilariño-Güell, C., Rajput, A., Milnerwood, A. J., Shah, B., Szu-Tu, C., Trinh, J., Yu, I., Encarnacion, M., Munsie, L. N., Tapia, L., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt570 · Cited by 313 · cited 1×
“[67] Vilariño-Güell C, Rajput A, Milnerwood AJ, Shah B, Szu-Tu C, Trinh J, et al.”
How much phenotypic variation can be attributed to parkin genotype?
Lohmann, E., Periquet, M., Bonifati, V., Wood, N. W., De Michele, G., Bonnet, A., Fraix, V., Broussolle, E., Horstink, M. W. I. M., Vidailhet, M., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10613 · Cited by 301
Self-citationTranslation Initiator EIF4G1 Mutations in Familial Parkinson Disease
Chartier-Harlin, M.-C., Dachsel, J. C., Vilariño-Güell, C., Lincoln, S. J., Leprêtre, F., Hulihan, M. M., Kachergus, J., Milnerwood, A. J., Tapia, L., Song, M.-S., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.08.009 · Cited by 299 · cited 2×
“in EIFG4, which encodes the eukaryotic translation initiation factor 4-gamma, were involved in autosomal dominant PD with late onset and Lewy body pathology [93].”
BackgroundParkin mutations are frequent in patients with isolated early‐onset parkinsonism
Periquet, M., Latouche, M., Lohmann, E., Rawal, N., De Michele, G., Ricard, S., Teive, H., Fraix, V., Vidailhet, M., Nicholl, D., et al. (2003) · Brain · doi:10.1093/brain/awg136 · Cited by 292 · cited 2×
“Mutations are highly diverse, including missense mutations and nonsense mutations, frameshifts, rearrangements with exon deletion or multiplications, but all of them lead to protein loss of function or absence of protein by nonsense mRNA decay [107,108,110,111].”
BackgroundSelf-citationLesage, S., Anheim, M., Condroyer, C., Pollak, P., Durif, F., Dupuits, C., Viallet, F., Lohmann, E., Corvol, J.-C., Honoré, A., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq454 · Cited by 287 · cited 24×
“The p.Ala53Thr mutation, which is the most frequent SNCA mutation, causes early onset PD (before age 50 years), sometimes resembling IPD but often associated with dementia [34–36].”
BackgroundInfluentialSelf-citationWilson, G. R., Sim, J. C. H., McLean, C., Giannandrea, M., Galea, C. A., Riseley, J. R., Stephenson, S. E. M., Fitzpatrick, E., Haas, S. A., Pope, K., et al. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.10.015 · Cited by 274 · cited 2×
“The neuropathological study of a male RAB39B case revealed the presence of Lewy bodies and Lewy neurites and a loss of pigmented neurons [101].”
BackgroundMutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis
Bras, J., Verloes, A., Schneider, S. A., Mole, S. E., & Guerreiro, R. J. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds089 · Cited by 266 · cited 2×
“phenotype also have neuronal and glial lipofuscin deposits in the cortex, cerebellum and basal nuclei [135].”
BackgroundPINK1-linked parkinsonism is associated with Lewy body pathology
Samaranch, L., Lorenzo-Betancor, O., Arbelo, J. M., Ferrer, I., Lorenzo, E., Irigoyen, J., Pastor, M. A., Marrero, C., Isla, C., Herrera-Henriquez, J., et al. (2010) · Brain · doi:10.1093/brain/awq051 · Cited by 258 · cited 2×
“[123] Samaranch L, Lorenzo-Betancor O, Arbelo JM, Ferrer I, Lorenzo E, Irigoyen J, et al.”
BackgroundGenome-wide Linkage Analysis of a Parkinsonian-Pyramidal Syndrome Pedigree by 500 K SNP Arrays
Shojaee, S., Sina, F., Banihosseini, S. S., Kazemi, M. H., Kalhor, R., Shahidi, G.-A., Fakhrai-Rad, H., Ronaghi, M., & Elahi, E. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.05.005 · Cited by 258
Paisán‐Ruiz, C., Guevara, R., Federoff, M., Hanagasi, H., Sina, F., Elahi, E., Schneider, S. A., Schwingenschuh, P., Bajaj, N., Emre, M., et al. (2010) · Movement Disorders · doi:10.1002/mds.23221 · Cited by 256 · cited 6×
“The symptoms at onset were highly variable, encompassing akineto-rigid syndrome [129,130], learning disability [131], motor fine task impairment [132,133] or behavioural disturbances [134].”
BackgroundInfluentialα-Synuclein gene duplication is present in sporadic Parkinson disease
Ahn, T. B., Kim, S. Y., Kim, J. Y., Park, S. S., Lee, D. S., Min, H. J., Kim, Y. K., Kim, S. E., Kim, J. M., Kim, H. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000271080.53272.c7 · Cited by 249
Giannandrea, M., Bianchi, V., Mignogna, M. L., Sirri, A., Carrabino, S., D'Elia, E., Vecellio, M., Russo, S., Cogliati, F., Larizza, L., et al. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.01.011 · Cited by 240 · cited 2×
“The phenotypic spectrum of RAB39B mutations has been extended to include autism spectrum disorder, seizures, and macrocephaly [103,104].”
BackgroundPhenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN)
Kurian, M. A., Morgan, N. V., MacPherson, L., Foster, K., Peake, D., Gupta, R., Philip, S. G., Hendriksz, C., Morton, J. E. V., Kingston, H. M., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000310986.48286.8e · Cited by 238 · cited 2×
“[140] Kurian MA, Morgan NV, MacPherson L, Foster K, Peake D, Gupta R, et al.”
BackgroundCalcium, Bioenergetics, and Neuronal Vulnerability in Parkinson's Disease
Surmeier, D. J., & Schumacker, P. T. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.410530 · Cited by 236
Sriram, S. R., Li, X., Ko, H. S., Chung, K. K. K., Wong, E., Lim, K. L., Dawson, V. L., & Dawson, T. M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi292 · Cited by 223 · cited 2×
“Mutations are highly diverse, including missense mutations and nonsense mutations, frameshifts, rearrangements with exon deletion or multiplications, but all of them lead to protein loss of function or absence of protein by nonsense mRNA decay [107,108,110,111].”
BackgroundPaisán-Ruiz, C., Li, A., Schneider, S. A., Holton, J. L., Johnson, R., Kidd, D., Chataway, J., Bhatia, K. P., Lees, A. J., Hardy, J., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.009 · Cited by 215
Parkinson’s disease in GTP cyclohydrolase 1 mutation carriers
Mencacci, N. E., Isaias, I. U., Reich, M. M., Ganos, C., Plagnol, V., Polke, J. M., Bras, J., Hersheson, J., Stamelou, M., Pittman, A. M., et al. (2014) · Brain · doi:10.1093/brain/awu179 · Cited by 201
Self-citationDNAJC6 Mutations Associated With Early‐Onset Parkinson's Disease
Olgiati, S., Quadri, M., Fang, M., Rood, J. P. M. A., Saute, J. A., Chien, H. F., Bouwkamp, C. G., Graafland, J., Minneboo, M., Breedveld, G. J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24553 · Cited by 197
Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese
Gwinn–Hardy, K., Chen, J. Y., Liu, H.-C., Liu, T. Y., Boss, M., Seltzer, W., Adam, A., Singleton, A., Koroshetz, W., Waters, C., et al. (2000) · Neurology · doi:10.1212/wnl.55.6.800 · Cited by 197 · cited 1×
“[64] Gwinn-Hardy K, Chen JY, Liu H-C, Liu TY, Boss M, Seltzer W, et al.”
BackgroundClinical features of LRRK2‐associated Parkinson's disease in central Norway
Aasly, J. O., Toft, M., Fernandez‐Mata, I., Kachergus, J., Hulihan, M., White, L. R., & Farrer, M. (2005) · Annals of Neurology · doi:10.1002/ana.20456 · Cited by 191 · cited 1×
“[19] Aasly JO, Toft M, Fernandez-Mata I, Kachergus J, Hulihan M, White LR, et al.”
BackgroundDNAJC6 is responsible for juvenile parkinsonism with phenotypic variability
Köroğlu, Ç., Baysal, L., Cetinkaya, M., Karasoy, H., & Tolun, A. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.11.006 · Cited by 190 · cited 7×
“[150] Köroğlu Ç , Baysal L, Cetinkaya M, Karasoy H, Tolun A.”
BackgroundInfluentialATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation
Schneider, S. A., Paisan‐Ruiz, C., Quinn, N. P., Lees, A. J., Houlden, H., Hardy, J., & Bhatia, K. P. (2010) · Movement Disorders · doi:10.1002/mds.22947 · Cited by 189 · cited 3×
“Brain MRI showed diffuse atrophy of cerebral and subcortical structures [129,134] or cerebellar atrophy [132].”
BackgroundAlzheimer's disease and Parkinson's disease: Comparison of speech and language alterations
Cummings, J. L., Darkins, A., Mendez, M., Hill, M. A., & Benson, D. F. (1988) · Neurology · doi:10.1212/wnl.38.5.680 · Cited by 183
Poor and protracted myelination as a contributory factor to neurodegenerative disorders
Braak, H., & Del Tredici, K. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.04.001 · Cited by 178
Mutations in the GIGYF2 (TNRC15) Gene at the PARK11 Locus in Familial Parkinson Disease
Lautier, C., Goldwurm, S., Dürr, A., Giovannone, B., Tsiaras, W. G., Pezzoli, G., Brice, A., & Smith, R. J. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.01.015 · Cited by 178 · cited 2×
“[74] Lautier C, Goldwurm S, Dürr A, Giovannone B, Tsiaras WG, Pezzoli G, et al.”
BackgroundSelf-citationEstimated life expectancy of Parkinson's patients compared with the UK population
Ishihara, L. S., Cheesbrough, A., Brayne, C., & Schrag, A. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.100107 · Cited by 173 · cited 2×
“[2] Ishihara LS, Cheesbrough A, Brayne C, Schrag A.”
BackgroundIdentification of TMEM230 mutations in familial Parkinson's disease
Deng, H.-X., Shi, Y., Yang, Y., Ahmeti, K. B., Miller, N., Huang, C., Cheng, L., Zhai, H., Deng, S., Nuytemans, K., et al. (2016) · Nature Genetics · doi:10.1038/ng.3589 · Cited by 172 · cited 2×
“synaptic vesicle trafficking and is a component of Lewy bodies and Lewy neurites [70].”
BackgroundLin, G., Lee, P.-T., Chen, K., Mao, D., Tan, K. L., Zuo, Z., Lin, W.-W., Wang, L., & Bellen, H. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.019 · Cited by 170 · cited 2×
“membrane fluidity and neuronal function impairment [137].”
BackgroundMeng, H., Yamashita, C., Shiba-Fukushima, K., Inoshita, T., Funayama, M., Sato, S., Hatta, T., Natsume, T., Umitsu, M., Takagi, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15500 · Cited by 170 · cited 2×
“[97] Meng H, Yamashita C, Shiba-Fukushima K, Inoshita T, Funayama M, Sato S, et al.”
BackgroundKilarski, L. L., Pearson, J. P., Newsway, V., Majounie, E., Knipe, M. D. W., Misbahuddin, A., Chinnery, P. F., Burn, D. J., Clarke, C. E., Marion, M., et al. (2012) · Movement Disorders · doi:10.1002/mds.25132 · Cited by 170
Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism?
Charles, P., Camuzat, A., Benammar, N., Sellal, F., Destée, A., Bonnet, A.-M., Lesage, S., Le Ber, I., Stevanin, G., Dürr, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000269323.21969.db · Cited by 166 · cited 7×
“The mean CAG repeat expansion in PD was 36.2 1.1 for PD versus 43.1 for SCA2 [60], but the major difference is that CAG repeats are interrupted in PD families with ATXN2 expansion whereas the repeats are pure in cases with SCA2 [61].”
BackgroundInfluentialSelf-citationEstrada-Cuzcano, A., Martin, S., Chamova, T., Synofzik, M., Timmann, D., Holemans, T., Andreeva, A., Reichbauer, J., De Rycke, R., Chang, D.-I., et al. (2017) · Brain · doi:10.1093/brain/aww307 · Cited by 166 · cited 2×
“More recently, recessive mutations in ATP13A2 were identified in patients with hereditary spastic paraplegia (SPG78), with a mean age at onset of 32 years, and were associated with parkinsonism in a single patient [136].”
BackgroundPhenotypic spectrum of patients with PLA2G6 mutation and PARK14 -linked parkinsonism
Yoshino, H., Tomiyama, H., Tachibana, N., Ogaki, K., Li, Y., Funayama, M., Hashimoto, T., Takashima, S., & Hattori, N. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f73649 · Cited by 165 · cited 2×
“Brain MRI showed global or frontal predominant cortical atrophy and, much later, iron deposition in some patients [145,146].”
BackgroundParkin Disease: A Clinicopathologic Entity?
Doherty, K. M., Silveira-Moriyama, L., Parkkinen, L., Healy, D. G., Farrell, M., Mencacci, N. E., Ahmed, Z., Brett, F. M., Hardy, J., Quinn, N., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.172 · Cited by 163
Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non‐Ashkenazi Jewish ancestry
Lee, A. J., Wang, Y., Alcalay, R. N., Mejia‐Santana, H., Saunders‐Pullman, R., Bressman, S., Corvol, J., Brice, A., Lesage, S., Mangone, G., et al. (2017) · Movement Disorders · doi:10.1002/mds.27059 · Cited by 161
Self-citationExhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia
Clot, F., Grabli, D., Cazeneuve, C., Roze, E. F., Castelnau, P., Chabrol, B., Landrieu, P., Nguyen, K., Ponsot, G., Abada-Bendib, M., et al. (2009) · Brain · doi:10.1093/brain/awp084 · Cited by 157 · cited 3×
“dopaminergic treatment (DYT5 # 128230) [56].”
BackgroundInfluentialSelf-citationThe many faces of alpha‐synuclein mutations
Kasten, M., & Klein, C. (2013) · Movement Disorders · doi:10.1002/mds.25499 · Cited by 154
Familial parkinsonism with synuclein pathology: Clinical and PET studies of A30P mutation carriers
Krüger, R., Kuhn, W., Leenders, K. L., Sprengelmeyer, R., Müller, T., Woitalla, D., Portman, A. T., Maguire, R. P., Veenma, L., Schröder, U., et al. (2001) · Neurology · doi:10.1212/wnl.56.10.1355 · Cited by 154
Mutant Parkin Impairs Mitochondrial Function and Morphology in Human Fibroblasts
Grünewald, A., Voges, L., Rakovic, A., Kasten, M., Vandebona, H., Hemmelmann, C., Lohmann, K., Orolicki, S., Ramirez, A., Schapira, A. H. V., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012962 · Cited by 152 · cited 2×
“[109] Grünewald A, Voges L, Rakovic A, Kasten M, Vandebona H, Hemmelmann C, et al.”
BackgroundIbáñez, P. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.555 · Cited by 152
Lesage, S., Leutenegger, A., Ibáñez, P., Janin, S., Lohmann, E., Dürr, A., & Brice, A. (2005) · The American Journal of Human Genetics · doi:10.1086/432422 · Cited by 152 · cited 1×
“[25] Lesage S, Leutenegger A-L, Ibanez P, Janin S, Lohmann E, Dürr A, et al.”
BackgroundSelf-citationLRRK2: Cause, Risk, and Mechanism
Paisán-Ruiz, C., Lewis, P. A., & Singleton, A. B. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130192 · Cited by 151
Quadri, M., Mandemakers, W., Grochowska, M. M., Masius, R., Geut, H., Fabrizio, E., Breedveld, G. J., Kuipers, D., Minneboo, M., Vergouw, L. J. M., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30179-0 · Cited by 143 · cited 4×
“The phenotype includes parkinsonism with poor response to levodopa or early onset of treated-induced dyskinesias [113,154,155].”
BackgroundInfluentialGenetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
A. Schneider, S., Dusek, P., Hardy, J., Westenberger, A., Jankovic, J., & P. Bhatia, K. (2013) · Current Neuropharmacology · doi:10.2174/157015913804999469 · Cited by 139 · cited 2×
“iron deposition in the basal ganglia, essentially in the globus pallidus [142].”
BackgroundPARK20 caused by SYNJ1 homozygous Arg258Gln mutation in a new Italian family
Olgiati, S., Rosa, A. D., Quadri, M., Criscuolo, C., Breedveld, G. J., Picillo, M., Pappatà, S., Quarantelli, M., Barone, P., Michele, G. D., et al. (2014) · Neurogenetics · doi:10.1007/s10048-014-0406-0 · Cited by 138 · cited 2×
“[157] Olgiati S, De Rosa A, Quadri M, Criscuolo C, Breedveld GJ, Picillo M, et al.”
BackgroundDJ-1 linked parkinsonism (PARK7) is associated with Lewy body pathology
Taipa, R., Pereira, C., Reis, I., Alonso, I., Bastos-Lima, A., Melo-Pires, M., & Magalhães, M. (2016) · Brain · doi:10.1093/brain/aww080 · Cited by 131 · cited 2×
“examination confirmed the hallmarks of PD, with presence of Lewy bodies and loss of neurons in the substantia nigra and locus coeruleus [127].”
BackgroundClinical spectrum of Kufor‐Rakeb syndrome in the Chilean kindred with ATP13A2 mutations
Behrens, M. I., Brüggemann, N., Chaná, P., Venegas, P., Kägi, M., Parrao, T., Orellana, P., Cristián Garrido, I., Rojas, C., Hauke, J., et al. (2010) · Movement Disorders · doi:10.1002/mds.22996 · Cited by 125 · cited 2×
“[131] Behrens MI, Brüggemann N, Chana P, Venegas P, Kägi M, Parrao T, et al.”
BackgroundKiely, A. P., Ling, H., Asi, Y. T., Kara, E., Proukakis, C., Schapira, A. H., Morris, H. R., Roberts, H. C., Lubbe, S., Limousin, P., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0038-3 · Cited by 124 · cited 1×
“[39] Kiely AP, Ling H, Asi YT, Kara E, Proukakis C, Schapira AH, et al.”
BackgroundThe role of glucocerebrosidase in Parkinson disease pathogenesis
Gegg, M. E., & Schapira, A. H. V. (2018) · The FEBS Journal · doi:10.1111/febs.14393 · Cited by 123 · cited 1×
“Mutations in GBA variably affect lysosomal activity and lead to a-Syn accumulation [173,174].”
BackgroundNew Genes Causing Hereditary Parkinson’s Disease or Parkinsonism
Puschmann, A. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0780-8 · Cited by 121 · cited 1×
“the mutation in ADORA1 (# 102775) because they presented a phenotype similar to that of the first PTRHD1 family [168].”
BackgroundOlfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease
Khan, N. L., Katzenschlager, R., Watt, H., Bhatia, K. P., Wood, N. W., Quinn, N., & Lees, A. J. (2004) · Neurology · doi:10.1212/01.wnl.0000118281.66802.81 · Cited by 120 · cited 1×
“[117] Khan NL, Katzenschlager R, Watt H, Bhatia KP, Wood NW, Quinn N, et al.”
BackgroundEngel, L. A., Jing, Z., O'Brien, D. E., Sun, M., & Kotzbauer, P. T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012897 · Cited by 119 · cited 2×
“tory mechanisms, thus accounting for the differences in phenotypes [147].”
BackgroundInoshita, T., Arano, T., Hosaka, Y., Meng, H., Umezaki, Y., Kosugi, S., Morimoto, T., Koike, M., Chang, H.-Y., Imai, Y., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx179 · Cited by 119 · cited 2×
“[47] Inoshita T, Arano T, Hosaka Y, Meng H, Umezaki Y, Kosugi S, et al.”
BackgroundSPG11 spastic paraplegia: A new cause of juvenile parkinsonism
Anheim, M., Lagier‐Tourenne, C., Stévanin, G., Fleury, M., Dürr, A., Namer, I. J., Denora, P. S., Brice, A., Mandel, J., Koenig, M., et al. (2009) · Journal of Neurology · doi:10.1007/s00415-009-0083-3 · Cited by 112 · cited 2×
“[158] Anheim M, Lagier-Tourenne C, Stevanin G, Fleury M, Durr A, Namer IJ, et al.”
BackgroundSelf-citationThe RAB39B p.G192R mutation causes X-linked dominant Parkinson’s disease
Mata, I. F., Jang, Y., Kim, C.-H., Hanna, D. S., Dorschner, M. O., Samii, A., Agarwal, P., Roberts, J. W., Klepitskaya, O., Shprecher, D. R., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0045-4 · Cited by 101 · cited 3×
“[102] Mata IF, Jang Y, Kim C-H, Hanna DS, Dorschner MO, Samii A, et al.”
BackgroundSCA2 may present as levodopa‐responsive parkinsonism
Payami, H., Nutt, J. G., Gancher, S., Bird, T. D., McNeal, M. G., Seltzer, W. K., Hussey, J., Lockhart, P. J., Gwinn, K. A., Singleton, A., et al. (2002) · Movement Disorders · doi:10.1002/mds.10375 · Cited by 100
R632W mutation in PLA2G6 segregates with dystonia‐parkinsonism in a consanguineous Iranian family
Sina, F., Shojaee, S. M., Elahi, E., & Paisán‐Ruiz, C. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02356.x · Cited by 93 · cited 1×
“[143] Sina F, Shojaee S, Elahi E, Paisán-Ruiz C.”
Loss-of-function mutations in RAB39B are associated with typical early-onset Parkinson disease
Lesage, S., Bras, J., Cormier-Dequaire, F., Condroyer, C., Nicolas, A., Darwent, L., Guerreiro, R., Majounie, E., Federoff, M., Heutink, P., et al. (2015) · Neurology Genetics · doi:10.1212/nxg.0000000000000009 · Cited by 92 · cited 2×
“Several additional cases with RAB39B loss-of-function mutations in males have been described [102,105].”
Self-citationParkin is linked to the ubiquitin pathway
Tanaka, K., Suzuki, T., Chiba, T., Shimura, H., Hattori, N., & Mizuno, Y. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100242 · Cited by 91 · cited 3×
“[108] Tanaka K, Suzuki T, Chiba T, Shimura H, Hattori N, Mizuno Y.”
BackgroundVPS35 mutation in Japanese patients with typical Parkinson's disease
Ando, M., Funayama, M., Li, Y., Kashihara, K., Murakami, Y., Ishizu, N., Toyoda, C., Noguchi, K., Hashimoto, T., Nakano, N., et al. (2012) · Movement Disorders · doi:10.1002/mds.25145 · Cited by 91
A multidisciplinary study of patients with early-onset PD with and without parkin mutations
Lohmann, E., Thobois, S., Lesage, S., Broussolle, E., du Montcel, S. T., Ribeiro, M.-J., Rémy, P., Pélissolo, A., Dubois, B., Mallet, L., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000327098.86861.d4 · Cited by 90 · cited 2×
“The Mini-Mental State Examination (MMSE) score is usually between 25/30 and 30/30 (mean: 28/30) [112,115,116].”
BackgroundSelf-citationα-Synuclein and Parkinsonism: Updates and Future Perspectives
Rosborough, K., Patel, N., & Kalia, L. V. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0737-y · Cited by 89
Taghavi, S., Chaouni, R., Tafakhori, A., Azcona, L. J., Firouzabadi, S. G., Omrani, M. D., Jamshidi, J., Emamalizadeh, B., Shahidi, G. A., Ahmadi, M., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0535-1 · Cited by 87 · cited 4×
“The phenotype includes parkinsonism with poor response to levodopa or early onset of treated-induced dyskinesias [113,154,155].”
BackgroundInfluentialThe LRRK2 G2019S mutation as the cause of Parkinson’s disease in Ashkenazi Jews
Thaler, A., Ash, E. L., Gan‐Or, Z., Orr‐Urtreger, A., & Giladi, N. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0303-0 · Cited by 78 · cited 2×
“[15] Thaler A, Ash E, Gan-Or Z, Orr-Urtreger A, Giladi N.”
BackgroundRagland, M. F., Hutter, C., Zabetian, C. P., & Edwards, K. L. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp288 · Cited by 75 · cited 1×
“[89] Ragland M, Hutter C, Zabetian C, Edwards K.”
BackgroundGenetic variation of Omi/HtrA2 and Parkinson's disease
Ross, O. A., Soto, A. I., Vilariño-Güell, C., Heckman, M. G., Diehl, N. N., Hulihan, M. M., Aasly, J. O., Sando, S., Gibson, J. M., Lynch, T., et al. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.08.003 · Cited by 72 · cited 2×
“Gly399Ser variant without confirmation in large-scale studies [81,82].”
BackgroundScreening for VPS35 mutations in Parkinson's disease
Sheerin, U.-M., Charlesworth, G., Bras, J., Guerreiro, R., Bhatia, K., Foltynie, T., Limousin, P., Silveira-Moriyama, L., Lees, A., & Wood, N. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.032 · Cited by 68 · cited 1×
“[52] Sheerin U-M, Charlesworth G, Bras J, Guerreiro R, Bhatia K, Foltynie T, et al.”
BackgroundJuvenile dystonia-parkinsonism and dementia caused by a novel ATP13A2 frameshift mutation
Crosiers, D., Ceulemans, B., Meeus, B., Nuytemans, K., Pals, P., Broeckhoven, C. V., Cras, P. P., & Theuns, J. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.10.011 · Cited by 66 · cited 2×
“[133] Crosiers D, Ceulemans B, Meeus B, Nuytemans K, Pals P, Van Broeckhoven C, et al.”
BackgroundHyposmia in G2019S LRRK2-related parkinsonism: Clinical and pathologic data
Silveira-Moriyama, L., Guedes, L. C., Kingsbury, A., Ayling, H., Shaw, K., Barbosa, E. R., Bonifati, V., Quinn, N. P., Abou-Sleiman, P., Wood, N. W., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000326575.20829.45 · Cited by 65
Fasano, D., Parisi, S., Pierantoni, G. M., De Rosa, A., Picillo, M., Amodio, G., Pellecchia, M. T., Barone, P., Moltedo, O., Bonifati, V., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0410-7 · Cited by 65 · cited 2×
“[152] Fasano D, Parisi S, Pierantoni GM, De Rosa A, Picillo M, Amodio G, et al.”
BackgroundIdentification of VPS35 mutations replicated in French families with Parkinson disease
Lesage, S., Condroyer, C., Klebe, S., Honoré, A., Tison, F., Brefel-Courbon, C., Dürr, A., Brice, A., Agid, Y., Anheim, M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318253d5f2 · Cited by 64 · cited 1×
“[51] Lesage S, Condroyer C, Klebe S, Honore A, Tison F, BrefelCourbon C, et al.”
BackgroundSelf-citationCHCHD2 and Parkinson's disease
Jansen, I. E., Brás, J., Lesage, S., Schulte, C., Gibbs, J. R., Nalls, M. A., Brice, A., Wood, N. W., Morris, H. R., Hardy, J., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00094-0 · Cited by 64
Self-citationWoodbury‐Smith, M., Deneault, É., Yuen, R. K. C., Walker, S., Zarrei, M., Pellecchia, G., Howe, J., Hoang, N., Uddin, M. J., Marshall, C. R., et al. (2017) · Molecular Autism · doi:10.1186/s13229-017-0175-3 · Cited by 62 · cited 2×
“The phenotypic spectrum of RAB39B mutations has been extended to include autism spectrum disorder, seizures, and macrocephaly [103,104].”
BackgroundLesage, S., Condroyer, C., Lannuzel, A., Lohmann, E., Troiano, A., Tison, F., Damier, P., Thobois, S., Ouvrard-Hernandez, A.-M., Rivaud-Péchoux, S., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.062612 · Cited by 62 · cited 3×
“[12] Lesage S, Condroyer C, Lannuzel A, Lohmann E, Troiano A, Tison F, et al.”
BackgroundSelf-citationDrouet, V., & Lesage, S. (2014) · BioMed Research International · doi:10.1155/2014/289728 · Cited by 61 · cited 1×
“[152,153] and leading to early-onset autosomal recessive”
Self-citationVPS35 Parkinson’s disease phenotype resembles the sporadic disease
The Austrian VPS-35 Investigators Team, Struhal, W., Presslauer, S., Spielberger, S., Zimprich, A. A., Auff, E., Bruecke, T., Poewe, W. H., & Ransmayr, G. N. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1179-1 · Cited by 60
Genetic causes of Parkinson?s disease: UCHL-1
Healy, D. G., Abou‐Sleiman, P. M., & Wood, N. W. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0917-3 · Cited by 57 · cited 1×
“[88] Healy DG, Abou-Sleiman PM, Wood NW.”
Lin, C.-H., Chen, M.-L., Chen, G. S., Tai, C.-H., & Wu, R.-M. (2011) · Human Genetics · doi:10.1007/s00439-011-1041-6 · Cited by 54 · cited 3×
“[83] Lin C-H, Chen M-L, Chen GS, Tai C-H, Wu R-M.”
BackgroundSudhaman, S., Muthane, U. B., Behari, M., Govindappa, S. T., Juyal, R. C., & Thelma, B. K. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103616 · Cited by 52 · cited 2×
“In vitro studies showed that mutations in RIC3 led to a decrease of CHRNA7 (a cholinergic receptor involved in calcium influx in neurons) on cell membranes [92].”
BackgroundMutation in ADORA1 identified as likely cause of early‐onset parkinsonism and cognitive dysfunction
Jaberi, E., Rohani, M., Shahidi, G. A., Nafissi, S., Arefian, E., Soleimani, M., Moghadam, A., Arzenani, M. K., Keramatian, F., Klotzle, B., et al. (2016) · Movement Disorders · doi:10.1002/mds.26627 · Cited by 49 · cited 1×
“[169] Jaberi E, Rohani M, Shahidi GA, Nafissi S, Arefian E, Soleimani M, et al.”
BackgroundNovel UCHL1 mutations reveal new insights into ubiquitin processing
Rydning, S. L., Backe, P. H., de Sousa, M. M. L., Iqbal, Z., Øye, A.-M., Sheng, Y., Yang, M., Lin, X., Slupphaug, G., Nordenmark, T. H., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx072 · Cited by 49 · cited 2×
“Recently, mutations in UCHL1 were reported in an autosomal recessive form of spastic paraplegia with early onset (SPG79) [90,91].”
BackgroundSudhaman, S., Prasad, K., Behari, M., Muthane, U. B., Juyal, R. C., & Thelma, B. K. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103459 · Cited by 45 · cited 2×
“Neither atypical signs nor cognitive decline were reported [167].”
BackgroundPTRHD1 (C2orf79) mutations lead to autosomal‐recessive intellectual disability and parkinsonism
Khodadadi, H., Azcona, L. J., Aghamollaii, V., Omrani, M. D., Garshasbi, M., Taghavi, S., Tafakhori, A., Shahidi, G. A., Jamshidi, J., Darvish, H., et al. (2016) · Movement Disorders · doi:10.1002/mds.26824 · Cited by 45
Deletion of theparkinandPACRGgene promoter in early-onset parkinsonism
Lesage, S., Periquet, M., Lohmann, E., Lacomblez, L., Teive, H. A. G., Janin, S., Cousin, P.-Y., Dürr, A., Brice, A., & for the French Parkinson Disease Genetics Study Group (2006) · Human Mutation · doi:10.1002/humu.20436 · Cited by 43 · cited 2×
“Furthermore, there are no phenotypical differences between patients with PRKN missense mutations and those with disruptive mutations [121].”
BackgroundSelf-citationHeckman, M. G., Soto‐Ortolaza, A. I., Aasly, J. O., Abahuni, N., Annesi, G., Bacon, J. A., Bardien, S., Bozi, M., Brice, A., Brighina, L., et al. (2013) · Movement Disorders · doi:10.1002/mds.25600 · Cited by 43
Self-citationMechanistic contributions of FBXO7 to Parkinson disease
Joseph, S., Schulz, J. B., & Stegmüller, J. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14253 · Cited by 42 · cited 1×
“[160] Joseph S, Schulz JB, Stegmüller J.”
Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease
Blauwendraat, C., Kia, D. A., Pihlstrøm, L., Gan‐Or, Z., Lesage, S., Gibbs, J. R., Ding, J., Alcalay, R. N., Hassin‐Baer, S., Pittman, A. M., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.012 · Cited by 42 · cited 1×
“[45] Blauwendraat C, Kia DA, Pihlstrøm L, Gan-Or Z, Lesage S, Gibbs JR, et al.”
BackgroundSelf-citationEIF4G1 in familial Parkinson's disease: pathogenic mutations or rare benign variants?
Lesage, S., Condroyer, C., Klebe, S., Lohmann, E., Durif, F., Damier, P., Tison, F., Anheim, M., Honoré, A., Viallet, F., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.05.006 · Cited by 41
Self-citationNovelUCHL1mutations reveal new insights into ubiquitin processing
Rydning, S. L., Backe, P. H., de Sousa, M. M. L., Iqbal, Z., Øye, A.-M., Sheng, Y., Yang, M., Lin, X., Slupphaug, G., Nordenmark, T. H., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw391 · Cited by 39
Clinical Heterogeneity of the LRRK2 G2019S Mutation
Papapetropoulos, S., Singer, C., Ross, O. A., Toft, M., Johnson, J. L., Farrer, M. J., & Mash, D. C. (2006) · Archives of Neurology · doi:10.1001/archneur.63.9.1242 · Cited by 39 · cited 1×
“[17] Papapetropoulos S, Singer C, Ross OA, Toft M, Johnson JL, Farrer MJ, et al.”
BackgroundMandel, H., Saita, S., Edvardson, S., Jalas, C., Shaag, A., Goldsher, D., Vlodavsky, E., Langer, T., & Elpeleg, O. N. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-103922 · Cited by 38 · cited 2×
“monogenic PD remains controversial and, recently, autosomal recessive (AR) mutations of HTRA2 were reported to be associated with 3-methylglutaconic aciduria, an infantile neurodegenerative disorder [85,86].”
BackgroundRubio, J. P., Topp, S. D., Warren, L. L., Jean, P. L. S., Wegmann, D., Kessner, D., Novembre, J., Shen, J., Fraser, D. J., Aponte, J. L., et al. (2012) · Human Mutation · doi:10.1002/humu.22075 · Cited by 36 · cited 1×
“[23] Rubio JP, Topp S, Warren L, St Jean PL, Wegmann D, Kessner D, et al.”
BackgroundGIGYF2 mutation in late-onset Parkinson’s disease with cognitive impairment
Ruiz‐Martínez, J., Krebs, C. E., Makarov, V., Gorostidi, A., Martí-Massó, J. F., & Paisán‐Ruiz, C. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.69 · Cited by 36 · cited 2×
“[78] Ruiz-Martinez J, Krebs CE, Makarov V, Gorostidi A, Martı́Massó JF, Paisán-Ruiz C.”
Backgroundα-Synuclein gene duplication is present in sporadic Parkinson disease
Brueggemann, N., Odin, P., Gruenewald, A., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000338439.00992.c7 · Cited by 36 · cited 1×
“[31] Brueggemann N, Odin P, Gruenewald A, Tadic V, Hagenah J, Seidel G, et al.”
BackgroundPARK11 gene (GIGYF2) variants Asn56Ser and Asn457Thr are not pathogenic for Parkinson's disease
Zimprich, A. A., Schulte, C., Reinthaler, E. M., Haubenberger, D., Balzar, J., Lichtner, P., Tawil, S. E., Edris, S., Foki, T., Pirker, W., et al. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2009.01.005 · Cited by 35 · cited 2×
“In one study, the authors did not find a strong association between mutations in GIGYF2 and PD, and the variant Asn457Thr, previously described as pathogenic, was found in three healthy controls [77].”
BackgroundOláhová, M., Thompson, K., Hardy, S. A., Barbosa, I. A., Besse, A., Anagnostou, M., White, K., Davey, T., Simpson, M. A., Champion, M., et al. (2016) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-016-9977-2 · Cited by 35 · cited 2×
“monogenic PD remains controversial and, recently, autosomal recessive (AR) mutations of HTRA2 were reported to be associated with 3-methylglutaconic aciduria, an infantile neurodegenerative disorder [85,86].”
BackgroundIdentification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease
Hatano, T., Funayama, M., Kubo, S.-I., Mata, I. F., Oji, Y., Mori, A., Zabetian, C. P., Waldherr, S. M., Yoshino, H., Oyama, G., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.05.025 · Cited by 33 · cited 2×
“Despite a highly variable age at onset, LRRK2 patients tended to have later onset PD [14].”
BackgroundUCHL1 S18Y variant is a risk factor for Parkinson’s disease in Japan
the Fukuoka Kinki Parkinson’s Disease Study Group, Miyake, Y., Tanaka, K., Fukushima, W., Kiyohara, C., Sasaki, S., Tsuboi, Y., Yamada, T., Oeda, T., Shimada, H., et al. (2012) · BMC Neurology · doi:10.1186/1471-2377-12-62 · Cited by 31 · cited 1×
“[87] Miyake Y, Tanaka K, Fukushima W, Kiyohara C, Sasaki S, Tsuboi Y, et al.”
BackgroundNejad, M. M., Shahidi, G. A., Rohani, M., Shojaee, S. M., Hashemi, M., Klotzle, B., Fan, J., & Elahi, E. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.06.023 · Cited by 31 · cited 6×
“[132] Malakouti-Nejad M, Shahidi G-A, Rohani M, Shojaee SM, Hashemi M, Klotzle B, et al.”
BackgroundInfluentialVaried pathological and therapeutic response effects associated withCHCHD2mutant and risk variants
Tio, M., Wen, R., Lim, Y. L., Zukifli, Z. H. B., Xie, S., Ho, P., Zhou, Z., Koh, T., Zhao, Y., & Tan, E. (2017) · Human Mutation · doi:10.1002/humu.23234 · Cited by 30
Giri, A., Mok, K. Y., Jansen, I. E., Sharma, M., Tesson, C., Mangone, G., Lesage, S., Brás, J., Shulman, J. M., Sheerin, U., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.10.004 · Cited by 28 · cited 4×
“[73] Giri A, Mok KY, Jansen I, Sharma M, Tesson C, Mangone G, et al.”
BackgroundInfluentialSelf-citationChen, Y., Chang, Y., Lan, M., Chen, P., & Lin, C. (2017) · BMC Neurology · doi:10.1186/s12883-017-0972-5 · Cited by 26 · cited 2×
“PD due to mutations in VPS35 is IPD-like except for an earlier age at onset [53,55].”
BackgroundEIF4G1 mutations do not cause Parkinson's disease
Nichols, N., Brás, J., Hernandez, D. G., Jansen, I. E., Lesage, S., Lubbe, S. J., & Singleton, A. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.017 · Cited by 26 · cited 4×
“Further studies did not support this finding and EIF4G1 may not be considered as an established causal gene for PD [94,95].”
BackgroundResultInfluentialSelf-citationParkinsonism in GTP cyclohydrolase 1 mutation carriers
Guella, I., Sherman, H. E., Appel‐Cresswell, S., Rajput, A. H., Rajput, A. H., & Farrer, M. J. (2014) · Brain · doi:10.1093/brain/awu341 · Cited by 25 · cited 2×
“[59] Guella I, Sherman HE, Appel-Cresswell S, Rajput A, Rajput AH, Farrer MJ.”
ResultA novel mutation of CHCHD2 p.R8H in a sporadic case of Parkinson's disease
Ikeda, A., Matsushima, T., Daida, K., Nakajima, S., Conedera, S., Li, Y., Yoshino, H., Oyama, G., Funayama, M., Nishioka, K., et al. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.10.018 · Cited by 21 · cited 2×
“Depression was observed without other psychiatric symptoms [99].”
BackgroundGenetic variations of Omi/HTRA2 in Chinese patients with Parkinson's disease
Wang, C., Xu, Q., Weng, L., Zhang, Q., Zhang, H., Guo, J., Tan, L., Tang, J., Yan, X., & Tang, B. (2011) · Brain Research · doi:10.1016/j.brainres.2011.02.037 · Cited by 20 · cited 2×
“However, two novel heterozygous mutations were identified in patients with levodopa-responsive early onset PD (mean age at onset about 55 years) [83,84].”
BackgroundMotor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls
Gunzler, S. A., Riley, D. E., Chen, S. G., Tatsuoka, C. M., Johnson, W. M., Mieyal, J. J., Walter, E. M., Whitney, C. M., Feng, I., Owusu-Dapaah, H., et al. (2018) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2018.03.025 · Cited by 20 · cited 1×
“[18] Gunzler SA, Riley DE, Chen SG, Tatsuoka CM, Johnson WM, Mieyal JJ, et al.”
BackgroundDNAJC13 mutation screening in patients with Parkinson's disease from South Italy
Gagliardi, M., Annesi, G., Procopio, R., Morelli, M., Iannello, G., Bonapace, G., Mancini, M., Nicoletti, G., & Quattrone, A. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.06.004 · Cited by 20 · cited 1×
“[69] Gagliardi M, Annesi G, Procopio R, Morelli M, Iannello G, Bonapace G, et al.”
BackgroundA new PLA2G6 mutation in a family with infantile neuroaxonal dystrophy
Iannello, G., Graziano, C., Cenacchi, G., Cordelli, D. M., Zuntini, R., Papa, V., Magistà, A. M., Gagliardi, M., Procopio, R., Quattrone, A., et al. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.08.3260 · Cited by 12 · cited 2×
“[141] Grazia I, Claudio G, Giovanna C, Maria CD, Roberta Z, Valentina P, et al.”
BackgroundVPS13C—Another Hint at Mitochondrial Dysfunction in Familial Parkinson's Disease
Schreglmann, S. R., & Houlden, H. (2016) · Movement Disorders · doi:10.1002/mds.26682 · Cited by 10
Screening for TMEM230 mutations in young-onset Parkinson's disease
Ma, D., Foo, J. N., Ng, E. Y., Zhao, Y., Liu, J., & Tan, E. K. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.011 · Cited by 10 · cited 2×
“However, several studies have reported no evidence of a role of TMEM230 mutation in the risk of PD [72,73].”
BackgroundNovel gene (TMEM230) linked to Parkinson’s disease
Olszewska, D. A., Fearon, C., & Lynch, T. (2016) · Journal of Clinical Movement Disorders · doi:10.1186/s40734-016-0046-7 · Cited by 7 · cited 1×
“A knock-out mouse model of TMEM230 shows defects in vesicle trafficking in neurons [71].”
BackgroundHuang, Y., Chen, X., He, X., Guo, C., Sun, X., Liang, F., Long, S., Lu, X.-L., Feng, L., Guo, W., et al. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6551 · Cited by 3 · cited 1×
“[50] Huang Y, Chen X, He X, Guo C, Sun X, Liang F, et al.”
Background
Cited by
Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy
Muzio, L., Viotti, A., & Martino, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.742065 · Cited by 581
“These genes encode for cytosolic proteins and include leucine-rich repeat kinase 2 (LRRK2, PARK8) and α-synuclein (SNCA, PARK1), which are interestingly linked to mitochondrial function modulation as well (Lunati et al., 2018).”
BackgroundLRRK2 in Parkinson disease: challenges of clinical trials
Tolosa, E., Vila, M., Klein, C., & Rascol, O. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0301-2 · Cited by 438
Enhancing glycolysis attenuates Parkinson’s disease progression in models and clinical databases
Cai, R., Zhang, Y., Simmering, J. E., Schultz, J. L., Li, Y., Fernandez-Carasa, I., Consiglio, A., Raya, A., Polgreen, P. M., Narayanan, N. S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129987 · Cited by 286
Depression in neurodegenerative diseases: Common mechanisms and current treatment options
Galts, C. P. C., Bettio, L. E. B., Jewett, D. C., Yang, C. C., Brocardo, P. S., Rodrigues, A. L. S., Thacker, J. S., & Gil-Mohapel, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.002 · Cited by 269
Alternative splicing in neurodegenerative disease and the promise of RNA therapies
Nikom, D., & Zheng, S. (2023) · Nature Reviews Neuroscience · doi:10.1038/s41583-023-00717-6 · Cited by 190
Metadata
- Authors
- Lunati, A., Lesage, S., & Brice, A.
- Venue
- Revue Neurologique
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 174
- Issue
- 9
- Pages
- 628-643
- ISSN
- 0035-3787 (ISSN-L)
- OpenAlex
- W2892058170
- Cited by
- 215
- References
- 165
- FWCI
- 14.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.